OneOme, co-founded by Mayo Clinic, empowers more informed prescription decisions through its RightMed® test and medication optimization platform. By analyzing a patient’s genes to help predict how he or she may respond to medications, OneOme’s pharmacogenomic platform helps healthcare providers make more informed prescription decisions to prevent adverse reactions and medication ineffectiveness. Fast Company named OneOme one of the World’s 50 Most Innovative Companies for 2018 (#2 in biotech; #22 overall), while Inc. declared it one of the five “biggest game-changing innovations in 2018.”
“Our mission is to make pharmacogenomics widely accessible to empower smarter prescription decisions and tackle one of the most expensive problems in healthcare,” said Paul Owen, CEO of OneOme. “The Smart Health Innovation Lab gives us the unique opportunity to work closely with leaders from the payor and provider side to work towards redefining the healthcare experience and increasing the adoption of pharmacogenomics.”
Smart Health Innovation Lab will connect OneOme with technologists from Aspire Ventures and experts from Capital BlueCross and Penn Medicine Lancaster General Health to gain direct exposure to payors and providers. With their help, OneOme will develop a better understanding of their needs and perspectives in the evolving healthcare market. Using the lab’s simulated healthcare environments, OneOme has the opportunity to strengthen its product and services and create a market-adoption blueprint to accelerate its growth.
The Smart Health Innovation Lab was developed collaboratively by Aspire Ventures, Capital BlueCross, Clio Health, and LG Health to advance technology aimed at improving health outcomes, lowering costs, and enhancing both the patient and provider experience. OneOme will be the third company to go through to the program, following Emovi and NeuroFlow.
“Every year, the U.S. spends an estimated $200 billion on unnecessary or inappropriate prescription drugs. By personalizing the drug to the patient, pharmacogenomics offers a better path to the proper medicine, a reduction in adverse drug reactions, and massive cuts to ineffective drug spending,” said Kim Ireland, CEO, Smart Health Innovation Lab. “Working with the Smart Health Innovation Lab, OneOme will be better positioned to address each of the quadruple aims in healthcare: improving the patient experience and outcomes, improving population health, decreasing the providers’ burden, and reducing costs.”
About Smart Health Innovation Lab
Smart Health Innovation Lab accelerates the growth of startups by fast-tracking their innovations to transform healthcare. Founded by Aspire Ventures, Capital BlueCross, Clio Health, and Penn Medicine Lancaster General Health, this unique lab and certification program gives startups mentorship from a network of experts, a testing environment to validate their products, and access to enterprise-level opportunities with a network of providers and payors. The result is a more efficient, more effective path to market adoption and insurance reimbursement.
OneOme was co-founded with Mayo Clinic to bring pharmacogenomics into routine clinical care. OneOme is a privately held company backed by early-stage venture firm Invenshure, LLC, and Mayo Clinic. To learn more about OneOme, visit oneome.com.
Editor's Note: Mayo Clinic has financial investment in the technology referenced in this news release. The revenue that Mayo Clinic will receive is used to support its not-for-profit mission in patient care, education and research.